TABLE 2.
Infection | Reportable as sexual abuse | Site(s) and specimen(s) | Recommended test(s) |
---|---|---|---|
N. gonorrhoeae | Diagnostic | Vagina, urethra (males), rectum, pharynx | Culture on selective media, isolates confirmed by at least 2 methods that use different principles; NAATsb may be used, but some NAATs may cross-react with other Neisseria species; specimens should be retained for additional testing; NAATs are not approved for rectal or pharyngeal specimens |
C. trachomatis | Diagnostica | Vagina, urethra (males), rectum, urine (if NAAT is used) | Culture (tissue culture, confirmation by staining with FA-conjugated species-specific monoclonal antibody with visualization of characteristic intracytoplasmic inclusions); NAATsb may be used if culture is not available; specimens should be retained for further testing; NAATs are not approved for rectal specimens |
Syphilis | Diagnostica | Serum, active lesions | Serology (initial screening with nontreponemal test, confirmation with treponemal test); dark-field microscopy to identify treponemes in lesions |
HSV | Suspicious | Lesions on vagina, urethra (males), rectum | Culture; screening using serology is not recommended |
T. vaginalis | Highly suspicious | Vagina | Examination of vaginal wet mount; culture |
HPV | Suspicious | Vagina, urethra (males), rectum | Physical examination; biopsy and HPV typing of lesions |
HIV | Diagnostica | Serum | EIA, followed by Western blot, viral load |
If perinatal acquisition can be ruled out.
Data on the use of NAATs in children are limited to SDA and TMA with vagina and urine from females.